WO2013100874A1 - Effervescent pregablin formulation - Google Patents
Effervescent pregablin formulation Download PDFInfo
- Publication number
- WO2013100874A1 WO2013100874A1 PCT/TR2012/000223 TR2012000223W WO2013100874A1 WO 2013100874 A1 WO2013100874 A1 WO 2013100874A1 TR 2012000223 W TR2012000223 W TR 2012000223W WO 2013100874 A1 WO2013100874 A1 WO 2013100874A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- effervescent
- formulation
- formulation according
- formulations
- pregabalin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title claims abstract description 40
- 238000009472 formulation Methods 0.000 title claims description 63
- 229960001233 pregabalin Drugs 0.000 claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 206010015037 epilepsy Diseases 0.000 claims abstract description 11
- 201000006474 Brain Ischemia Diseases 0.000 claims abstract description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 5
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 5
- 208000008238 Muscle Spasticity Diseases 0.000 claims abstract description 5
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 5
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims abstract description 5
- 208000015114 central nervous system disease Diseases 0.000 claims abstract description 5
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 5
- 208000004296 neuralgia Diseases 0.000 claims abstract description 5
- 208000018198 spasticity Diseases 0.000 claims abstract description 5
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 4
- 208000000094 Chronic Pain Diseases 0.000 claims abstract description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims abstract description 4
- 208000001640 Fibromyalgia Diseases 0.000 claims abstract description 4
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims abstract description 4
- 206010041250 Social phobia Diseases 0.000 claims abstract description 4
- 208000020431 spinal cord injury Diseases 0.000 claims abstract description 4
- 239000013543 active substance Substances 0.000 claims description 23
- 239000000796 flavoring agent Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 239000003765 sweetening agent Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000007938 effervescent tablet Substances 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 239000007911 effervescent powder Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 238000005550 wet granulation Methods 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 235000001055 magnesium Nutrition 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 235000010755 mineral Nutrition 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 239000001361 adipic acid Substances 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 238000007907 direct compression Methods 0.000 claims description 2
- 238000007908 dry granulation Methods 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229960003975 potassium Drugs 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- 239000001508 potassium citrate Substances 0.000 claims description 2
- 229960002635 potassium citrate Drugs 0.000 claims description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 2
- 235000011082 potassium citrates Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 239000011720 vitamin B Substances 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 description 10
- 206010010904 Convulsion Diseases 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 239000007909 solid dosage form Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000009747 swallowing Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Natural products OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 235000005805 Prunus cerasus Nutrition 0.000 description 1
- 244000207449 Prunus puddum Species 0.000 description 1
- 235000009226 Prunus puddum Nutrition 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940009697 lyrica Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Definitions
- the present invention relates to effervescent pharmaceutical compositions comprising pregabalin and use of these compositions in the treatment of epilepsy, central nervous system disorders, Parkinson's disease; Huntington's disease; tardive dyskinesia; spasticity; cerebral ischemia; postherpetic neuralgia; social phobia; fibromyalgia and spinal cord injury induced chronic pains; neuropathic pains associated with diabetic peripheral neuropathy and common anxiety disorder.
- Pregabalin (Lyrica®) is a gamma-aminobutyric acid (GABA) analogue and it has anxiolytic, analgesic and anti-epileptic activity.
- GABA gamma-aminobutyric acid
- Chemical structure of pregabalin having the chemical name of (S)- 3-(aminomethyl)-5-methylhexanoic acid is illustrated with Formula I.
- pregabalin displaces [3H]-gabapentin by binding to sub-unit of voltage-gated calcium channels in central nervous system.
- Pregabalin reduces release of many neurotransmitters including glutamate, noradrenaline and substance P. It is used in treatment of epilepsy, simple or complex partial convulsion either accompanied or not by secondary generalized convulsions, and neuropathic pain.
- Pregabalin was first disclosed in the patent numbered EP 0641330 Bl. Processes for preparation of pregabalin, pregabalin salts and use of pregabalin in treatment of central nervous system disorders, epilepsy, Parkinson's disease, Huntington's disease, tardive dyskinesia, spasticity and cerebral ischemia are described in said patent.
- Epilepsy is a neurological disorder-disease emerging as a result of an abnormal electrochemical discharge of neurons in the brain. It results from excessive and uncontrolled dissemination of electricity related to normal brain operation. It frequently causes temporary loss of consciousness. In a simplified way, epilepsy seizure is caused by short-time brain dysfunction. It emerges as a result of temporary electricity disturbance in brain cells. No specific cause has been detected in approximately half of the patients while possible problems in prenatal brain development, natal problems, meningitis, brain infection, brain tumours, intoxications or serious head injuries may cause epileptic seizures in a particular group of patients.
- epilepsy symptoms vary among people, the major symptoms are principally loss of consciousness, fainting, shivering, falling, inattentive staring, shortness of breath, asphyxia, cyanosis of the tissues and face, excessive salivation, urinary incontinence, uncontrolled movements, post- seizure confusion and somnolence. Epilepsy seizures may occur at any age, however it frequently affects the youngest and the eldest.
- WO 2008008120 discloses a solid dosage form comprising a compacted filling material comprising at least one active agent and at least one of disintegrant and wetting agent.
- solid dosage forms such as tablet or capsule are disadvantageous for paediatric and geriatric patients and for those having swallowing difficulties. In addition, they are not preferred by most of the patients.
- suspension forms are not mostly preferred for the reasons that they carry the possibility of uncontrolled dose intake, their production costs are high, they have physical and chemical instability problems, they pose problems during use and carrying phases.
- suspension forms have higher bioavailability values as compared to solid dosage forms, it is seen that they are more inconvenient than solid dosage forms when considered in terms of stability and shelf-life.
- the pharmaceutical compositions comprising pregabalin have been prepared in the form of tablet, solution and forms for injection.
- use of tablet dosage form poses problems for those who have swallowing difficulties (children, elderly and disabled people etc.) or for those who do not want to swallow tablets or capsules.
- Solution dosage forms are not preferred since they carry the possibility of uncontrolled dose intake, have bad taste and cause difficulty of use. In addition, they complicate compliance of the patient with the treatment and they have low stability and they have shorter shelf-life than solid dosage forms.
- Forms for injection are not preferred because they have some disadvantages in terms of administration.
- the inventors have surprisingly found that the problems existing in the prior art can be solved with the effervescent formulations prepared according to the subject of the present invention.
- the present invention discloses new, user-friendly, therapeutically advantageous effervescent formulations comprising pregabalin which have fast dissolution and/or dispersion and higher bioavailability as compared to solid dosage forms in the prior art.
- the formulations are in effervescent powder, tablet and granule forms having the advantages of both tablet and suspension forms and they remove the problems encountered in said dosage forms.
- Effervescent dosage forms are beneficial especially for the patients having swallowing difficulties and for paediatrics.
- compositions of the present invention comprise effervescent oral dosage forms and their pharmaceutical formulations comprising only the active agents or the active agents together with pharmaceutically acceptable excipients.
- the present invention provides a pharmaceutical composition in effervescent form comprising pregabalin optionally together with at least one pharmaceutically acceptable excipient.
- pregabalin comprised in the composition of the present invention can be in the form of free base, its pharmaceutically acceptable salt, racemate, solvate, hydrate, anhydrate, different polymorphic form and amorphous form, though it is preferably in free base form.
- effervescent formulations according to the present invention are used as dissolved in a glass of water or in another suitable liquid. At this point, it is apparent that water solubility of the formulation is a very important parameter in order to provide an effective treatment and therefore bioavailability.
- a characteristic feature of the effervescent formulations of the present invention is that said formulations comprise pregabalin having an average particle size less than 50 ⁇ as the active agent.
- another characteristic feature of the effervescent formulations of the present invention is that they comprise pregabalin having an average particle size in the range of 1 ⁇ to 50 ⁇ as the active agent.
- another characteristic feature of the effervescent formulations of the present invention is that they comprise pregabalin having an average particle size in the range of 1 ⁇ to 45 ⁇ as the active agent.
- a characteristic feature of the present invention is that the ratio of the active agent is in the range of 0.1- 60% by weight, preferably in the range of 1- 20% by weight in total formulation.
- the effervescent formulations of the present invention can be prepared in the form of effervescent powder, tablet and granule comprising at least one pharmaceutically acceptable excipient selected from effervescent couple, flavouring agent, solvent and solvent mixtures, binder, lubricant, sweetener and taste regulating agent in addition to the active agent pregabalin.
- the characteristic feature of the effervescent formulations of the present invention is that said formulations comprise at least one pharmaceutically acceptable effervescent couple in the range of 80 - 95% by weight.
- effervescent couple refers to to the combination comprising at least one effervescent acid and at least one effervescent base.
- total formulation comprises the effervescent acid in the range of 30 - 70% by weight, preferably in the range of 40-55% by weight and the effervescent base in the range of 20-60% by weight, preferably in the range of 30-40% by weight.
- the pharmaceutically acceptable effervescent acids that can be used in the effervescent formulations of the present invention are selected from a group comprising organic acids such as citric acid and acetic acid, tartaric acid, fumaric acid, adipic acid, malic acid or combinations thereof.
- the pharmaceutically acceptable effervescent bases that can be used in the effervescent formulations of the present invention are selected from a group comprising potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate and sodium hydrogen carbonate or combinations thereof.
- the pharmaceutical formulation according to the present invention is characterized by dissolving quickly and comprising flavouring agent, solvent and solvent mixtures, binder, lubricant, sweetener, taste regulating agent and effervescent base.
- effervescent powder, tablet and granule refers to effervescent tablets, effervescent granules, effervescent powders, effervescent tablets.
- the pharmaceutically acceptable taste regulating agent of the present invention can be selected from a group comprising sodium chloride, potassium chloride or combinations thereof.
- the present invention comprises saccharose, aspartame, sodium chloride or a mixture comprising a combination thereof as the taste regulating agent.
- the pharmaceutically acceptable sweetener of the present invention can be selected from a group comprising acesulfame potassium, acesulfame, aspartame, fructose, dextrose, glucose, lactitol, maltitol, xylitol, sorbitol, maltose, saccharine, saccharine sodium, sodium cyclamate, sucralose, sucrose or combinations thereof.
- the pharmaceutically acceptable binder of the present invention can be selected from a group comprising ethyl cellulose, hydroxyethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, sorbitol, gelatine, hypromellose, magnesium aluminium silicate, maltodextrin, polyethylene oxide, polyvinylpyrrolidone, povidone and water or combinations thereof.
- the pharmaceutically acceptable lubricant of the present invention can be selected from a group comprising magnesium stearate, polyethylene glycol 4000 (Peg 4000), polyethylene glycol 6000 (Peg 6000), sodium lauryl sulphate, starch, talc or combinations thereof.
- the pharmaceutically acceptable flavouring agent of the present invention can be selected from a group comprising sour cherry flavour, grapefruit flavour, lemon flavour, grape flavour, pear flavour, orange flavour, apricot flavour or combinations thereof.
- the formulation of the present invention can be combined with another active agent.
- another active agent used herein refers to various vitamins and/or minerals required for human body.
- Dosage forms can be taken separately, together or sequentially, though they can also be taken by combining pregabalin with other said active agent or agents in a single dosage form for combined therapy.
- the other active agent or agents that can be used together with pregabalin in combined therapy can be minerals such as calcium, potassium, magnesium, iron, sodium, zinc or their salts such as carbonate, sulphate; vitamins such as vitamin A, B vitamins such as Bi, B 12 , B 6 and/or folic acid, vitamin C, vitamin D, vitamin E.
- vitamins such as vitamin A, B vitamins such as Bi, B 12 , B 6 and/or folic acid, vitamin C, vitamin D, vitamin E.
- One or two of the other active agents listed above can be combined with pregabalin in combined therapy.
- the present invention comprises binary and ternary combinations of pregabalin with the other active agents explained above.
- the other active agent or agents that can be used in combined therapy can be produced together with pregabalin and by the same production method, though they can also be prepared by producing the active agent formulations separately and then combining them.
- the production method of the effervescent formulations according to the present invention can be any method in the prior art. Wet granulation, dry granulation, dry blending, direct compression or combinations thereof can be given as example of said methods. Though, the method prefferred in the present invention is wet granulation.
- the production method of the invention is preferably as follows:
- the effervescent composition of the present invention comprises
- At least one other pharmaceutically acceptable excipient in the range of 0.1 - 5% by weight.
- composition of the present invention can be used in prevention of the seizures, in reducing the number of the seizures or in the treatment of the disease of the patients diagnosed with epilepsy.
- the composition of the present invention can be prepared as a drug composition which is effective in the treatment of epilepsy, central nervous system disorders, Parkinson's disease; Huntington's disease; tardive dyskinesia; spasticity; cerebral ischemia; postherpetic neuralgia; social phobia; fibromyalgia and spinal cord injury induced chronic pains; neuropathic pains associated with diabetic peripheral neuropathy and common anxiety disorder.
- the present invention relates to administration of said composition to the mammals including human.
- the pharmaceutical composition of the present invention and preparation methods of this composition can be explained with the examples below. Yet, the invention should not be limited to these examples.
- Effervescent dosage form comprising pregabalin
- the effervescent couple and taste regulating agent are granulated with a pharmaceutically acceptable binder.
- Granulation solution used herein can comprise any solvent in addition to the binder.
- the granules are dried.
- Pregabalin and sweetener are added into this composition.
- the flavouring agent and lubricant are added and the composition is finalised.
- tablet compression is performed.
- Effervescent dosage form comprising pregabalin and vitamin B 12 in combined form
- the composition comprising pregabalin, vitamin B 12 and basic agent is granulated with at least one pharmaceutically acceptable binder.
- the granulation solution used herein can comprise any solvent in addition to the binder.
- the granules are dried and sieved.
- the effervescent acid, taste regulating agent and binder are mixed and added into this composition. They are granulated and the granules are dried.
- the sweetener, flavouring agent and lubricant are added and the composition is finalised.
- tablet compression is performed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a pharmaceutical composition in effervescent form comprising pregabalin and use of this composition in the treatment of epilepsy, central nervous system disorders, Parkinson's disease; Huntington's disease; tardive dyskinesia; spasticity; cerebral ischemia; postherpetic neuralgia; social phobia; fibromyalgia and spinal cord injury induced chronic pains; neuropathic pains associated with diabetic peripheral neuropathy and common anxiety disorder.
Description
EFFERVESCENT PREGABLIN FORMULATION
The present invention relates to effervescent pharmaceutical compositions comprising pregabalin and use of these compositions in the treatment of epilepsy, central nervous system disorders, Parkinson's disease; Huntington's disease; tardive dyskinesia; spasticity; cerebral ischemia; postherpetic neuralgia; social phobia; fibromyalgia and spinal cord injury induced chronic pains; neuropathic pains associated with diabetic peripheral neuropathy and common anxiety disorder.
Pregabalin (Lyrica®) is a gamma-aminobutyric acid (GABA) analogue and it has anxiolytic, analgesic and anti-epileptic activity. Chemical structure of pregabalin having the chemical name of (S)- 3-(aminomethyl)-5-methylhexanoic acid is illustrated with Formula I.
Formula I
It is known that pregabalin displaces [3H]-gabapentin by binding to sub-unit of voltage-gated calcium channels in central nervous system. Pregabalin reduces release of many neurotransmitters including glutamate, noradrenaline and substance P. It is used in treatment of epilepsy, simple or complex partial convulsion either accompanied or not by secondary generalized convulsions, and neuropathic pain.
Pregabalin was first disclosed in the patent numbered EP 0641330 Bl. Processes for preparation of pregabalin, pregabalin salts and use of pregabalin in treatment of central nervous system disorders, epilepsy, Parkinson's disease, Huntington's disease, tardive dyskinesia, spasticity and cerebral ischemia are described in said patent.
Epilepsy is a neurological disorder-disease emerging as a result of an abnormal electrochemical discharge of neurons in the brain. It results from excessive and uncontrolled dissemination of electricity related to normal brain operation. It frequently causes temporary loss of consciousness.
In a simplified way, epilepsy seizure is caused by short-time brain dysfunction. It emerges as a result of temporary electricity disturbance in brain cells. No specific cause has been detected in approximately half of the patients while possible problems in prenatal brain development, natal problems, meningitis, brain infection, brain tumours, intoxications or serious head injuries may cause epileptic seizures in a particular group of patients. Although epilepsy symptoms vary among people, the major symptoms are principally loss of consciousness, fainting, shivering, falling, inattentive staring, shortness of breath, asphyxia, cyanosis of the tissues and face, excessive salivation, urinary incontinence, uncontrolled movements, post- seizure confusion and somnolence. Epilepsy seizures may occur at any age, however it frequently affects the youngest and the eldest.
The patent application numbered WO 2008008120 discloses a solid dosage form comprising a compacted filling material comprising at least one active agent and at least one of disintegrant and wetting agent.
However, solid dosage forms such as tablet or capsule are disadvantageous for paediatric and geriatric patients and for those having swallowing difficulties. In addition, they are not preferred by most of the patients.
An alternative for removing this problem can be to formulate the pharmaceutical composition in suspension form. However suspension forms are not mostly preferred for the reasons that they carry the possibility of uncontrolled dose intake, their production costs are high, they have physical and chemical instability problems, they pose problems during use and carrying phases. Although suspension forms have higher bioavailability values as compared to solid dosage forms, it is seen that they are more inconvenient than solid dosage forms when considered in terms of stability and shelf-life.
In the prior art, the pharmaceutical compositions comprising pregabalin have been prepared in the form of tablet, solution and forms for injection. However, use of tablet dosage form poses problems for those who have swallowing difficulties (children, elderly and disabled people etc.) or for those who do not want to swallow tablets or capsules. Solution dosage forms are not preferred since they carry the possibility of uncontrolled dose intake, have bad taste and cause difficulty of use. In addition, they complicate compliance of the patient with the treatment and they have low stability and they have shorter shelf-life than solid dosage forms. Forms for injection, on the other hand, are not preferred because they have some disadvantages in terms of administration.
When the prior art is taken into consideration, it has been seen that there is need for new, user-friendly dosage forms comprising pregabalin which have fast dissolution and impact, long shelf life and also which are convenient for patients who have swallowing difficulties.
The inventors have surprisingly found that the problems existing in the prior art can be solved with the effervescent formulations prepared according to the subject of the present invention.
The present invention discloses new, user-friendly, therapeutically advantageous effervescent formulations comprising pregabalin which have fast dissolution and/or dispersion and higher bioavailability as compared to solid dosage forms in the prior art.
The characteristic feature of the present is that the formulations are in effervescent powder, tablet and granule forms having the advantages of both tablet and suspension forms and they remove the problems encountered in said dosage forms. Effervescent dosage forms are beneficial especially for the patients having swallowing difficulties and for paediatrics.
The pharmaceutical compositions of the present invention comprise effervescent oral dosage forms and their pharmaceutical formulations comprising only the active agents or the active agents together with pharmaceutically acceptable excipients.
In another aspect, the present invention provides a pharmaceutical composition in effervescent form comprising pregabalin optionally together with at least one pharmaceutically acceptable excipient.
In another aspect, pregabalin comprised in the composition of the present invention can be in the form of free base, its pharmaceutically acceptable salt, racemate, solvate, hydrate, anhydrate, different polymorphic form and amorphous form, though it is preferably in free base form.
The effervescent formulations according to the present invention are used as dissolved in a glass of water or in another suitable liquid. At this point, it is apparent that water solubility of the formulation is a very important parameter in order to provide an effective treatment and therefore bioavailability.
The inventors have found that the highest solubility is obtained with the effervescent formulations comprising the active agent pregabalin having an average particle size less than 50 μπι.
According to this, a characteristic feature of the effervescent formulations of the present invention is that said formulations comprise pregabalin having an average particle size less than 50 μιη as the active agent.
In another aspect, another characteristic feature of the effervescent formulations of the present invention is that they comprise pregabalin having an average particle size in the range of 1 μιη to 50 μπι as the active agent.
In another aspect, another characteristic feature of the effervescent formulations of the present invention is that they comprise pregabalin having an average particle size in the range of 1 μπι to 45 μπι as the active agent. In another aspect, a characteristic feature of the present invention is that the ratio of the active agent is in the range of 0.1- 60% by weight, preferably in the range of 1- 20% by weight in total formulation.
The effervescent formulations of the present invention can be prepared in the form of effervescent powder, tablet and granule comprising at least one pharmaceutically acceptable excipient selected from effervescent couple, flavouring agent, solvent and solvent mixtures, binder, lubricant, sweetener and taste regulating agent in addition to the active agent pregabalin.
The characteristic feature of the effervescent formulations of the present invention is that said formulations comprise at least one pharmaceutically acceptable effervescent couple in the range of 80 - 95% by weight.
The term "effervescent couple" refers to to the combination comprising at least one effervescent acid and at least one effervescent base.
Another characteristic feature of the effervescent formulations of the present invention is that total formulation comprises the effervescent acid in the range of 30 - 70% by weight, preferably in the range of 40-55% by weight and the effervescent base in the range of 20-60% by weight, preferably in the range of 30-40% by weight.
The pharmaceutically acceptable effervescent acids that can be used in the effervescent formulations of the present invention are selected from a group comprising organic acids such as citric acid and acetic acid, tartaric acid, fumaric acid, adipic acid, malic acid or combinations thereof.
The pharmaceutically acceptable effervescent bases that can be used in the effervescent formulations of the present invention are selected from a group comprising potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate and sodium hydrogen carbonate or combinations thereof. In another aspect, the pharmaceutical formulation according to the present invention is characterized by dissolving quickly and comprising flavouring agent, solvent and solvent mixtures, binder, lubricant, sweetener, taste regulating agent and effervescent base.
The term "effervescent powder, tablet and granule" refers to effervescent tablets, effervescent granules, effervescent powders, effervescent tablets. The pharmaceutically acceptable taste regulating agent of the present invention can be selected from a group comprising sodium chloride, potassium chloride or combinations thereof. Preferably, the present invention comprises saccharose, aspartame, sodium chloride or a mixture comprising a combination thereof as the taste regulating agent.
The pharmaceutically acceptable sweetener of the present invention can be selected from a group comprising acesulfame potassium, acesulfame, aspartame, fructose, dextrose, glucose, lactitol, maltitol, xylitol, sorbitol, maltose, saccharine, saccharine sodium, sodium cyclamate, sucralose, sucrose or combinations thereof.
The pharmaceutically acceptable binder of the present invention can be selected from a group comprising ethyl cellulose, hydroxyethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, sorbitol, gelatine, hypromellose, magnesium aluminium silicate, maltodextrin, polyethylene oxide, polyvinylpyrrolidone, povidone and water or combinations thereof.
The pharmaceutically acceptable lubricant of the present invention can be selected from a group comprising magnesium stearate, polyethylene glycol 4000 (Peg 4000), polyethylene glycol 6000 (Peg 6000), sodium lauryl sulphate, starch, talc or combinations thereof.
The pharmaceutically acceptable flavouring agent of the present invention can be selected from a group comprising sour cherry flavour, grapefruit flavour, lemon flavour, grape flavour, pear flavour, orange flavour, apricot flavour or combinations thereof.
The formulation of the present invention can be combined with another active agent.
The term "another active agent" used herein refers to various vitamins and/or minerals required for human body.
Dosage forms can be taken separately, together or sequentially, though they can also be taken by combining pregabalin with other said active agent or agents in a single dosage form for combined therapy.
The other active agent or agents that can be used together with pregabalin in combined therapy can be minerals such as calcium, potassium, magnesium, iron, sodium, zinc or their salts such as carbonate, sulphate; vitamins such as vitamin A, B vitamins such as Bi, B12, B6 and/or folic acid, vitamin C, vitamin D, vitamin E. One or two of the other active agents listed above can be combined with pregabalin in combined therapy. In other words, the present invention comprises binary and ternary combinations of pregabalin with the other active agents explained above.
The other active agent or agents that can be used in combined therapy can be produced together with pregabalin and by the same production method, though they can also be prepared by producing the active agent formulations separately and then combining them.
The production method of the effervescent formulations according to the present invention can be any method in the prior art. Wet granulation, dry granulation, dry blending, direct compression or combinations thereof can be given as example of said methods. Though, the method prefferred in the present invention is wet granulation. The production method of the invention is preferably as follows:
1. Obtaining the granulation solution by mixing at least one pharmaceutically acceptable binder and at least one solvent and optionally another active agent,
2. Mixing a pharmaceutically effective amount of pregabalin and at least another pharmaceutically acceptable excipient dryly,
3. Wet granulating the obtained dry mixture with the granulation solution obtained in the first step,
4. Drying the obtained granules and sieving them,
5. Adding at least one pharmaceutically acceptable sweetener into the dry granules and mixing them,
6. Sending the granules to any one of the tablet compression, bottle filling or sachet filling machines to obtain the desired dosage form.
The effervescent composition of the present invention comprises
- Pregabalin in the range of 1 -20% by weight,
- Effervescent acid in the range of 40-55% by weight,
- Effervescent base in the range of 30-40% by weight and
- At least one other pharmaceutically acceptable excipient in the range of 0.1 - 5% by weight.
In another aspect, the composition of the present invention can be used in prevention of the seizures, in reducing the number of the seizures or in the treatment of the disease of the patients diagnosed with epilepsy.
In another aspect, the composition of the present invention can be prepared as a drug composition which is effective in the treatment of epilepsy, central nervous system disorders, Parkinson's disease; Huntington's disease; tardive dyskinesia; spasticity; cerebral ischemia; postherpetic neuralgia; social phobia; fibromyalgia and spinal cord injury induced chronic pains; neuropathic pains associated with diabetic peripheral neuropathy and common anxiety disorder.
In another aspect, the present invention relates to administration of said composition to the mammals including human. The pharmaceutical composition of the present invention and preparation methods of this composition can be explained with the examples below. Yet, the invention should not be limited to these examples.
Example 1:
Effervescent dosage form comprising pregabalin;
The effervescent couple and taste regulating agent are granulated with a pharmaceutically acceptable binder. Granulation solution used herein can comprise any solvent in addition to the binder. The granules are dried. Pregabalin and sweetener are added into this composition. The flavouring agent and lubricant are added and the composition is finalised. Optionally, tablet compression is performed.
Example 2:
Effervescent dosage form comprising pregabalin and vitamin B12 in combined form;
The composition comprising pregabalin, vitamin B12 and basic agent is granulated with at least one pharmaceutically acceptable binder. The granulation solution used herein can comprise any solvent in addition to the binder. The granules are dried and sieved. The effervescent acid, taste regulating agent and binder are mixed and added into this composition. They are granulated and the granules are dried. The sweetener, flavouring agent and lubricant are added and the composition is finalised. Optionally, tablet compression is performed.
Claims
1. A pharmaceutical formulation comprising pregabalin, characterized in that said composition is in effervescent form.
2. The effervescent formulation according to claim 1, characterized in that the amount of pregabalin in the pharmaceutical formulations is in the range of 0.1-60% by weight in total formulation.
3. The effervescentformulation according to claim 2, characterized in that the amount of pregabalin in the pharmaceutical formulations is in the range of 0.1-20% by weight in total formulation.
4. The pharmaceutical formulation according to any preceding claims, characterized in that said formulation comprises at least one pharmaceutically acceptable excipient.
5. The effervescent formulation according to claim 4, characterized in that said composition comprises effervescent couple, binder, flavouring agent, lubricant, sweetener and taste regulating agent as the excipient.
6. The effervescent formulation according to claim 5, wherein the amount of the effervescent couple comprised in the formulation is in the range of 80-95% by weight in total formulation.
7. The effervescent formulation according to claim 5-6, characterized in that the effervescent couple used in the formulations is composed of the combination of at least one effervescent acid and at least one effervescent base
8. The effervescent formulation according to claim 7, characterized in that at least one effervescent acid used in the formulations is selected from a group comprising citric acid, acetic acid, tartaric acid, fumaric acid, adipic acid, malic acid, or combinations thereof.
9. The effervescent formulation according to claims 8, characterized in that said formulations comprise the effervescent acid in the range of 30 - 70% by weight, by weight in total formulation.
10. The effervescent formulation according to 8-9, characterized in that said formulations comprise the effervescent acid in the range of 40-55% by weight in total formulation.
11. The effervescent formulation according to claim 7, characterized in that the effervescent base used in the formulations is selected from a group comprising, potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate, and sodium hydrogen carbonate or combinations thereof.
12. The effervescent formulation according to claim 11, characterized in that said formulations comprise the effervescent base in the range of 20-60% by weight in total formulation.
13. The effervescent formulation according to claim 11-12, characterized in that said formulations comprise the effervescent base in the range of 30-40 % by weight in total formulation
14. The effervescent formulation according to any preceding claims 1, characterized in that average particle size of pregabalin in the formulations is less than 50 μπι.
15. The effervescent formulation according to claim 14, characterized in that average particle size of pregabalin in the formulations is in the range of 1 - 50 μιη.
16. The pharmaceutical composition according to claim 14-15, characterized in that average particle size of pregabalin in the formulations is in the range of 1 - 45 μιη
17. The effervescent formulation according to any preceding claims, characterized in that said formulation can be in the form of effervescent tablet, effervescent granule, effervescent powder.
18. The effervescent formulation according to any preceding claims characterized in that said formulations comprise optionally another active agent.
19. The effervescent formulation according to claim 18, characterized in that another active agent is selected from a group comprising minerals such as calcium, potassium, magnesium, iron, sodium, zinc, or their salts such as carbonate, sulphate; vitamins such as vitamin A, B vitamins such as Bj, Bj2 , and/or folic acid or combinations thereof
20. The effervescent formulation according to any one of the preceding claims, characterized in that said formulation is produced by any one of wet granulation, dry granulation, dry blending and direct compression methods.
21. The method according to claim 20, characterized in that said method is wet granulation method.
22. The effervescent formulation according to any preceding claims, characterized in that said formulation is used in the treatment of epilepsy, central nervous system disorders, Parkinson's disease; Huntington's disease; tardive dyskinesia; spasticity; cerebral ischemia; postherpetic neuralgia; social phobia; fibromyalgia and spinal cord injury induced chronic pains; neuropathic pains associated with diabetic peripheral neuropathy and common anxiety disorder.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2011/125579 | 2011-12-19 | ||
TR201112579 | 2011-12-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013100874A1 true WO2013100874A1 (en) | 2013-07-04 |
Family
ID=47997763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2012/000223 WO2013100874A1 (en) | 2011-12-19 | 2012-12-19 | Effervescent pregablin formulation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013100874A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2826470A1 (en) * | 2013-07-19 | 2015-01-21 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of pregabalin |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007048223A2 (en) * | 2005-10-25 | 2007-05-03 | Pharmascience Inc. | A gastric retention drug delivery system |
US20090304602A1 (en) * | 2008-06-06 | 2009-12-10 | Tuchinsky David B | Nutritional supplement |
WO2011053265A2 (en) * | 2009-11-02 | 2011-05-05 | Bilgic Mahmut | The parmaceutical compositions comprising calcium and vitamin d |
WO2012016683A2 (en) * | 2010-08-03 | 2012-02-09 | Ratiopharm Gmbh | Oral dosage form of pregabalin |
-
2012
- 2012-12-19 WO PCT/TR2012/000223 patent/WO2013100874A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007048223A2 (en) * | 2005-10-25 | 2007-05-03 | Pharmascience Inc. | A gastric retention drug delivery system |
US20090304602A1 (en) * | 2008-06-06 | 2009-12-10 | Tuchinsky David B | Nutritional supplement |
WO2011053265A2 (en) * | 2009-11-02 | 2011-05-05 | Bilgic Mahmut | The parmaceutical compositions comprising calcium and vitamin d |
WO2012016683A2 (en) * | 2010-08-03 | 2012-02-09 | Ratiopharm Gmbh | Oral dosage form of pregabalin |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2826470A1 (en) * | 2013-07-19 | 2015-01-21 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of pregabalin |
WO2015007890A1 (en) * | 2013-07-19 | 2015-01-22 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of pregabalin |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60213861T2 (en) | ORODISPERIGIBLE TABLETS WITH FEXOFENADINE | |
JP4903900B2 (en) | Pharmaceutical composition comprising levetiracetam | |
TWI522100B (en) | Formulations containing nalbuphine and uses thereof | |
EP2749270B1 (en) | Racecadotril and pharmaceutical compositions thereof | |
EP2563340A2 (en) | Water soluble pharmaceutical composition | |
WO2023078604A1 (en) | Formulations of psilocybin analogs and methods of use | |
WO2005120463A1 (en) | Rapidly disintegrating tablets of risperidone | |
EP2255810A1 (en) | Pharmaceutical forms comprising vardenafil and having a controlled bioavailability | |
EP2408424A2 (en) | Dry processing of retigabine | |
WO2011072839A1 (en) | Orodispersible tablet, containing dapoxetine | |
JP7146644B2 (en) | Pharmaceutical composition containing safinamide | |
EP2849733B1 (en) | Effervescent pharmaceutical formulations comprising pregabalin and vitamin b12 | |
EP2566448A2 (en) | Efervescent formulations comprising cefdinir | |
WO2013100874A1 (en) | Effervescent pregablin formulation | |
CN106511264A (en) | Methylphenidate hydrochloride oral solution and preparation method thereof | |
JP2002512953A (en) | Oral formulation of biguanide drug | |
WO2014104989A1 (en) | Pharmaceutical compositions comprising aripiprazole | |
MX2013012827A (en) | Oral liquid composition comprising divalproex sodium and process for preparing thereof. | |
EP3173077B1 (en) | Tablet formulations of nimesulide and thiocolchicoside | |
US9763878B2 (en) | Microgranular formulation including coagulation unit comprising discontinuous phase and continuous phase | |
KR102544141B1 (en) | Controlled release formulation for administration of Lacosamide | |
EP2905020A1 (en) | Effervescent formulations comprising ibuprofen and N-acetylcystein | |
WO2013080271A1 (en) | Analgesic | |
WO2013100879A1 (en) | Pharmaceutical compositions comprising quetiapine | |
WO2013100873A1 (en) | Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12834602 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12834602 Country of ref document: EP Kind code of ref document: A1 |